These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 17210593)

  • 1. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients.
    Rossert J; Gassmann-Mayer C; Frei D; McClellan W
    Nephrol Dial Transplant; 2007 Mar; 22(3):794-800. PubMed ID: 17210593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epoetin delta is effective for the management of anaemia associated with chronic kidney disease.
    Spinowitz BS; Pratt RD;
    Curr Med Res Opin; 2006 Dec; 22(12):2507-13. PubMed ID: 17166333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial.
    Macdougall IC; Temple RM; Kwan JT
    Nephrol Dial Transplant; 2007 Mar; 22(3):784-93. PubMed ID: 16968726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review.
    Germain M; Ram CV; Bhaduri S; Tang KL; Klausner M; Curzi M
    Nephrol Dial Transplant; 2005 Oct; 20(10):2146-52. PubMed ID: 15985516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration.
    Pussell BA; Walker R
    Nephrology (Carlton); 2007 Apr; 12(2):120-5. PubMed ID: 17371332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualizing anaemia treatment: a discussion of case histories.
    Muirhead N
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi37-43. PubMed ID: 15958826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years.
    Jacobs C; Frei D; Perkins AC
    Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii3-24. PubMed ID: 15824128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Iron deficiency is a common cause of bad response to epoetin treatment. It's important to follow iron status--not only the Hb value].
    Wallerstedt SM; Ljungman S; Broms E; Andrén L
    Lakartidningen; 2005 Sep 12-18; 102(37):2550-1, 2553-5. PubMed ID: 16200900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
    Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
    Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial.
    Keown PA; Churchill DN; Poulin-Costello M; Lei L; Gantotti S; Agodoa I; Gitlin M; Gandra SR; Mayne TJ
    Hemodial Int; 2010 Apr; 14(2):168-73. PubMed ID: 20345390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
    Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
    Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects.
    Bailie GR; Eisele G; Liu L; Roys E; Kiser M; Finkelstein F; Wolfe R; Port F; Burrows-Hudson S; Saran R
    Nephrol Dial Transplant; 2005 Jun; 20(6):1110-5. PubMed ID: 15769809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease.
    Benz R; Schmidt R; Kelly K; Wolfson M
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):215-21. PubMed ID: 17699416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of early correction of anemia on the progression of CKD.
    Rossert J; Levin A; Roger SD; Hörl WH; Fouqueray B; Gassmann-Mayer C; Frei D; McClellan WM
    Am J Kidney Dis; 2006 May; 47(5):738-50. PubMed ID: 16632012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of switching from subcutaneous to intravenous administration of epoetin-alpha in haemodialysis patients: results from a Swedish multicentre survey.
    Linde T; Furuland H; Wikström B
    Scand J Urol Nephrol; 2005; 39(4):329-33. PubMed ID: 16118109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
    Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
    Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.